Top Page
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
(6821)
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) vs. iShares MSCI Hong Kong ETF (EWH)
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Business Overview & Revenue Model
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.95B | 5.80B | 7.83B | 10.26B | 4.64B | 3.15B | Gross Profit |
| 2.51B | 2.46B | 4.00B | 4.86B | 2.06B | 1.47B | EBIT |
| 1.14B | 1.08B | 2.57B | 3.73B | 1.19B | 816.89M | EBITDA |
| 1.14B | 1.58B | 3.03B | 4.08B | 1.41B | 973.69M | Net Income Common Stockholders |
| 993.59M | 948.95M | 2.27B | 3.30B | 1.07B | 722.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.57B | 7.33B | 9.02B | 7.44B | 6.64B | 2.12B | Total Assets |
| 19.45B | 19.29B | 19.77B | 18.24B | 15.16B | 7.16B | Total Debt |
| 273.88M | 282.53M | 118.71M | 138.35M | 434.49M | 10.22M | Net Debt |
| ― | ― | -6.99B | -5.15B | -5.80B | -2.11B | Total Liabilities |
| 2.25B | 2.43B | 2.26B | 2.54B | 2.55B | 1.16B | Stockholders Equity |
| 17.18B | 16.85B | 17.48B | 15.65B | 12.61B | 5.99B |
| Cash Flow | Free Cash Flow | ||||
| 207.47M | 124.33M | 2.31B | 1.14B | ― | ― | Operating Cash Flow |
| 0.00 | 1.25B | 3.55B | 3.29B | 113.15M | 569.29M | Investing Cash Flow |
| 843.99M | ― | ― | ― | ― | ― | Financing Cash Flow |
| ― | ― | -542.03M | ― | 6.21B | 2.27B |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Technical Analysis
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$33.66B | 23.59 | 5.72% | 2.77% | -15.81% | -48.17% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
| $10.37B | 42.63 | 6.14% | 1.32% | ― | ― | ||
| $12.98B | 16.93 | 13.20% | 4.42% | ― | ― | ||
| $1.38B | 15.40 | 3.53% | ― | ― | ― | ||
| $12.79B | 28.17 | 8.17% | ― | ― | ― | ||
| €3.76B | 8.39 | 3.02% | ― | ― |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Corporate Events
Asymchem Laboratories (Tianjin) Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared in accordance with Chinese Accounting Standards and International Financial Reporting Standards. The report, which has been reviewed by the company’s audit committee, confirms the accuracy and completeness of the disclosed information, although it has not been audited by independent auditors. This announcement underscores the company’s commitment to transparency and adherence to regulatory standards, potentially reinforcing investor confidence.
Asymchem Laboratories (Tianjin) Co., Ltd. has announced that its board of directors will meet on April 23, 2025, to review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
Asymchem Laboratories (Tianjin) Co., Ltd. announced the results of its first extraordinary general meeting and class meetings for A and H shares of 2025, held on April 3, 2025. The meetings were conducted both on-site and online, with a significant number of shareholders participating. The resolutions proposed at these meetings were voted on, with certain shareholders required to abstain from voting on specific resolutions. The outcomes of these meetings are crucial for the company’s governance and strategic decisions, impacting its operational and market positioning.
Asymchem Laboratories reported a significant decline in its financial performance for the year ended December 31, 2024, with revenue decreasing by 25.40% and net profit attributable to shareholders dropping by 58.17% compared to the previous year. The company announced a proposed dividend distribution plan, which is subject to shareholder approval, despite the challenging financial results.
Asymchem Laboratories (Tianjin) Co., Ltd. has announced a final cash dividend of RMB 11 per 10 shares for the year ending December 31, 2024. The announcement, dated March 28, 2025, outlines that the dividend is ordinary in nature and requires shareholder approval on June 11, 2025. Details regarding the Hong Kong dollar equivalent, exchange rate, ex-dividend date, and other related information are yet to be announced. This dividend announcement reflects the company’s financial health and commitment to providing returns to its shareholders, potentially enhancing its market position and investor confidence.
Asymchem Laboratories (Tianjin) Co., Ltd. has announced proposed amendments to its articles of association following changes in its registered capital due to the repurchase and cancellation of certain A shares. These amendments reflect a decrease in the company’s registered capital and a slight adjustment in its shareholding structure. The proposed changes are subject to shareholder approval and are part of the company’s ongoing efforts to optimize its capital structure.
Asymchem Laboratories (Tianjin) Co., Ltd. has announced the convening of its first extraordinary general meeting of 2025, scheduled for April 3rd. The meeting will address several key resolutions, including the approval of the H Share Restricted Share Scheme and the 2025 A Share Scheme. These initiatives aim to enhance the company’s share incentive structures and align management interests with shareholder value. The meeting will also consider amendments to the Articles of Association and the repurchase and cancellation of restricted A Shares granted under the 2020 scheme, reflecting the company’s strategic focus on optimizing its corporate governance and shareholder engagement.
Asymchem Laboratories has announced the first H shares class meeting of 2025, scheduled for April 3, 2025, in Tianjin, PRC. The meeting will address special resolutions including the repurchase and cancellation of part of the restricted A shares under the 2020 Incentive Scheme and amendments to the Articles of Association. This meeting is significant as it involves strategic decisions that may impact the company’s share structure and governance, potentially affecting stakeholders and market positioning.
Asymchem Laboratories (Tianjin) Co., Ltd. has announced that its board of directors will convene on March 28, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend payment, highlighting the company’s ongoing commitment to shareholder value.
Asymchem Laboratories has completed the repurchase and cancellation of a portion of its A shares, reducing its issued share capital. This move, authorized by the company’s board, aims to implement an employee share ownership plan and will not affect the company’s controlling shareholder or its financial condition.
Asymchem Laboratories (Tianjin) Co., Ltd. has completed the repurchase of 12,300,701 A shares, representing 3.6161% of its total A Shares, through centralized price bidding using self-owned funds. This strategic repurchase aims to implement the company’s employee share ownership plan and share incentive scheme, as well as to cancel and reduce registered capital. The repurchase will not alter the company’s controlling shareholders or have a material impact on its operating results, ensuring compliance with Shenzhen and Hong Kong stock exchange regulations.